U.S. Markets closed

Prima Biomed Ltd. (PBMD)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.28-0.07 (-2.98%)
At close: 3:57PM EDT
People also watch
Full screen
Previous Close2.35
Bid2.28 x 600
Ask7.40 x 100
Day's Range2.26 - 2.44
52 Week Range0.51 - 3.26
Avg. Volume34,110
Market Cap43.82M
PE Ratio (TTM)-7.60
EPS (TTM)-0.3
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.25
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Operational Update

    SYDNEY, Australia, June 26, 2017-- Prima BioMed Ltd, has provided an update on the Company’ s two active clinical trials in IMP321. Prima is pleased to advise that clinical studies of IMP321 are progressing ...

  • GlobeNewswire23 days ago

    LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial

    SYDNEY, Australia, June 04, 2017-- Breast cancer clinical trial demonstrates LAG-3Ig is safe and well tolerated Data shows IMP321 in combination with chemotherapy leads to a sustainable increase in antigen ...

  • GlobeNewswire27 days ago

    Prima BioMed Announces Formation of Clinical Advisory Board

    New Clinical Advisory Board comprises team of internationally renowned clinicians Provides strategic advice for clinical development of lead drug candidate IMP321 in AIPAC metastatic breast cancer trial. ...